Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 100,263,744
  • Shares Outstanding, K 2,458,650
  • Annual Sales, $ 37,798 M
  • Annual Income, $ 1,236 M
  • 36-Month Beta 0.97
  • Price/Sales 2.64
  • Price/Cash Flow 10.18
  • Price/Book 14.85

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.45 +1.11%
on 04/27/17
42.76 -4.35%
on 03/30/17
-1.51 (-3.56%)
since 03/28/17
3-Month
38.68 +5.74%
on 01/30/17
42.82 -4.48%
on 03/27/17
+2.17 (+5.60%)
since 01/27/17
52-Week
37.20 +9.95%
on 12/08/16
45.58 -10.27%
on 08/02/16
-2.46 (-5.67%)
since 04/28/16

Most Recent Stories

More News
Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More

Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.

MRK : 62.33 (-0.40%)
LLY : 82.06 (+0.90%)
NVS : 77.03 (-0.04%)
PFE : 33.92 (+0.18%)
GSK : 40.90 (+0.29%)
SNY : 47.30 (+0.83%)
BMY : 56.05 (+0.68%)
Gout Therapeutics Market to Reach $8.3 Billion by 2025 - Key Vendors are Takeda Pharmaceutical, Novartis, Savient Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Merck, Teijin Pharma & Regeneron - Research and Markets

Research and Markets has announced the addition of the "Gout Therapeutics Market, 2014 - 2025" report to their offering.

TINLY : 19.3500 (+0.36%)
MRK : 62.33 (-0.40%)
GSK : 40.90 (+0.29%)
Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View

GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with...

MYL : 37.35 (-0.98%)
GRFS : 21.71 (+2.55%)
INFI : 2.15 (+2.38%)
GSK : 40.90 (+0.29%)
Glaxo (GSK) Beats Earnings and Revenues in Q1

Glaxo reported core earnings of 63 cents per American depositary share, which marginally beat our consensus estimate of 62 cents.

GSK : 40.90 (+0.29%)
Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More

Here we have four pharma companies that are set to report first-quarter results on Apr 26. Let's see how things are shaping up for this quarter.

JNJ : 123.47 (-0.22%)
MDCO : 49.32 (+1.52%)
AMGN : 163.32 (+0.37%)
GSK : 40.90 (+0.29%)
UTHR : 125.70 (+4.32%)
What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?

GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.

CLDX : 3.33 (-0.89%)
NVS : 77.03 (-0.04%)
GILD : 68.55 (-0.04%)
GSK : 40.90 (+0.29%)
BioAxone BioSciences Appoints Dr. Catherine Sohn to Lead Corporate Development

BioAxone BioSciences, Inc., a clinical-stage biotechnology company focused on developing innovative drugs to restore neurological function, today announced the appointment of Catherine Angell...

CUR : 4.74 (-1.46%)
LNDC : 13.75 (-1.79%)
JAZZ : 159.28 (-1.69%)
GSK : 40.90 (+0.29%)
Global Monoclonal Antibody Therapeutics Market: Emergence of New Products to Generate Growth Opportunities for Players

ALBANY, New York, April 20, 2017 /PRNewswire/ --

BAYRY : 124.4280 (+1.48%)
MRK : 62.33 (-0.40%)
NVS : 77.03 (-0.04%)
GSK : 40.90 (+0.29%)
PFE : 33.92 (+0.18%)
Global Monoclonal Antibody Therapeutics Market: Emergence of New Products to Generate Growth Opportunities for Players

The global market for Monoclonal Antibody Therapeutics is expected to witness a high level of competition in the next few years, thanks to the rising number of players entering the market, states a research...

BAYRY : 124.4280 (+1.48%)
MRK : 62.33 (-0.40%)
NVS : 77.03 (-0.04%)
GSK : 40.90 (+0.29%)
PFE : 33.92 (+0.18%)
Research and Markets - Global Antiviral Drugs Market to Grow at a CAGR of 9.48%, 2017-2021 with Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead Sciences & GlaxoSmithKline Leading the Market

DUBLIN, April 18, 2017 /PRNewswire/ --

GSK : 40.90 (+0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Support & Resistance

2nd Resistance Point 41.11
1st Resistance Point 41.01
Last Price 40.90
1st Support Level 40.72
2nd Support Level 40.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.